Affordable Access

Publisher Website

Adherence to imatinib therapy in patients with gastrointestinal stromal tumors

Authors
Journal
Cancer Treatment Reviews
0305-7372
Publisher
Elsevier
Volume
40
Issue
2
Identifiers
DOI: 10.1016/j.ctrv.2013.07.005
Keywords
  • Gastrointestinal Stromal Tumors
  • Imatinib
  • Adherence
Disciplines
  • Biology
  • Education
  • Medicine

Abstract

Abstract Imatinib mesylate, an oral tyrosine kinase inhibitor, is indicated for first-line treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors (GIST). Imatinib also is approved as adjuvant therapy for patients following resection of primary GIST. Despite the efficacy of imatinib for the treatment of patients with GIST, adherence to treatment can prove difficult. Clinical studies have identified a number of factors that have a significant association with non-adherence to therapy, including age >51years, female sex, a high number of concomitant medications, and complications with patients’ therapy or the disease itself. Moreover, treatment-related adverse events and increased healthcare costs have been shown to have an impact on patients’ adherence to therapy. A study of perceptions of adherence to therapy found discrepancies between actual and perceived adherence rates; both patients and physicians overestimate adherence to treatment. Non-adherence to treatment is not exclusive to oncology, and occurs in other disease areas, particularly with chronic conditions. Evidence from other disease areas suggests that routine assessment of adherence and the implementation of adherence programs can lead to improvements in health status and reduced healthcare costs. Improving patient adherence to imatinib treatment for patients with unresectable/metastatic GIST is particularly important, because non-adherence has a significant impact on clinical outcomes and healthcare costs. Therefore, the effective management of treatment-related adverse events along with patient education may be important in keeping patients compliant with continuous therapy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Adherence to imatinib therapy in gastrointestinal...

on Supportive care in cancer : of... August 2013

Adjuvant imatinib therapy for gastrointestinal str...

on Journal of Surgical Oncology December 2011

Neoadjuvant and adjuvant therapy with imatinib for...

on Asian Pacific journal of cance... 2011
More articles like this..